Search results for "Statin"

showing 10 items of 545 documents

Effects of fluvastatin slow-release (XL 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes.

2005

The lipid triad is the association of small, dense (sd) low-density lipoprotein (LDL), low high-density lipoprotein (HDL), and hypertriglyceridemia, all of which play a role in coronary artery disease in patients with type 2 diabetes. Although statins have demonstrated clear positive effects on cardiovascular morbidity/mortality in patients with diabetes and on single components of the lipid triad, it remains controversial whether they affect all components of the triad in these patients. Therefore, we performed a single-center, parallel-group, prospective, randomized, open-label, blinded-endpoint (PROBE)-type comparison of fluvastatin extended-release (XL) 80 mg (n=48) and simvastatin 20 m…

Malemedicine.medical_specialtySimvastatinIndolesHDLApolipoprotein BSmall dense LDLType 2 diabetesTriglycerideLDLFatty Acids MonounsaturatedFluvastatin XLInternal medicineDiabetes mellitusType 2 diabetes mellitusmedicineHumansPharmacology (medical)Prospective StudiesFluvastatinAgedHypertriglyceridemiabiologybusiness.industryAnticholesteremic AgentsApoA-IHypertriglyceridemianutritional and metabolic diseasesType 2 Diabetes MellitusGeneral MedicineMiddle Agedmedicine.diseaseLipoproteins LDLEndocrinologyDiabetes Mellitus Type 2SimvastatinDelayed-Action Preparationsbiology.proteinlipids (amino acids peptides and proteins)FemaleApoBbusinessLipoproteins HDLFluvastatinmedicine.drugLipoproteinAdvances in therapy
researchProduct

Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol \textless70 mg/dL During 5 Years After Ischemic Stroke

2020

Background and Purpose— The TST trial (Treat Stroke to Target) evaluated the benefit of targeting a LDL (low-density lipoprotein) cholesterol of <70 mg/dL to reduce the risk of cardiovascular events in 2860 patients with ischemic stroke with atherosclerotic stenosis of cerebral vasculature or aortic arch plaque >4 mm, in a French and Korean population. The follow-up lasted a median of 5.3 years in French patients (similar to the median follow-up time in the SPARCL trial [Stroke Prevention by Aggressive Reduction in Cholesterol Level]) and 2.0 years in Korean patients. Exposure duration to statin is a well-known driver for cardiovascular risk reduction. We report here the TST results …

Malemedicine.medical_specialtyStatinTime Factorsmedicine.drug_class[SDV]Life Sciences [q-bio]Brain IschemiaLDLchemistry.chemical_compoundDrug Delivery SystemsEzetimibeInternal medicinemedicineClinical endpointHumansangiographyMyocardial infarctionStrokeAgedAdvanced and Specialized NursingCerebral infarctionCholesterolbusiness.industryAnticholesteremic Agentsinformed consentcholesterolCholesterol LDLMiddle Agedmedicine.diseaseEzetimibestroke[SDV] Life Sciences [q-bio]aortachemistryNumber needed to treatCardiologyFemaleNeurology (clinical)Cardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and …

2009

Abstract Background Effects independent from cholesterol reduction on vascular function are considered to importantly contribute to the beneficial effects of statin therapy in cardiovascular disease. We aimed to evaluate the effect of high versus low dose atorvastatin on endothelial dysfunction in patients with coronary artery disease (CAD) in a setting of comparable cholesterol reduction. Methods and results Fifty-eight patients with CAD were randomly assigned to double-blind treatment for 8 weeks with atorvastatin 80mg per day (A80) or atorvastatin 10mg+ezetimibe 10mg per day (A10E10), respectively. Flow-mediated vasodilation (FMD) of the brachial artery, nitroglycerin-mediated endotheliu…

Malemedicine.medical_specialtyStatinmedicine.drug_classAtorvastatinCoronary Artery DiseaseCoronary artery diseasechemistry.chemical_compoundEzetimibeDouble-Blind Methodmedicine.arteryInternal medicinemedicineAtorvastatinHumansPyrrolescardiovascular diseasesEndothelial dysfunctionBrachial arteryAgedbiologybusiness.industryCholesterolAnticholesteremic AgentsCholesterol LDLMiddle Agedmedicine.diseaseAtherosclerosisEzetimibeEndocrinologyC-Reactive ProteinCholesterolTreatment OutcomechemistryHeptanoic AcidsHMG-CoA reductaseCardiologybiology.proteinAzetidineslipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugAtherosclerosis
researchProduct

Statin Use and Knee Osteoarthritis Outcomes: A Longitudinal Cohort Study

2018

Objective: Statins have several pleiotropic effects, but the literature regarding the possible relationship between use of statins and outcomes in knee osteoarthritis (OA) is limited. The aim of this study was to investigate whether statin use is associated with a lower risk of radiographic OA (ROA), radiographic symptomatic knee OA, and pain in North American individuals. Methods: A total of 4,448 community-dwelling adults from the Osteoarthritis Initiative were followed for 4 years. Statin use (including the time from baseline and the type of statin) was defined through self-report information and confirmed by a trained interviewer. Knee OA outcomes included incident ROA, symptomatic knee…

Malemedicine.medical_specialtyStatinmedicine.drug_classAtorvastatinPROGRESSIONOsteoarthritisLower riskTHERAPYArticleCohort Studies03 medical and health sciences0302 clinical medicineRheumatologyInternal medicinemedicineHumansEPIDEMIOLOGYRosuvastatinLongitudinal StudiesSCALEAgedddc:616030203 arthritis & rheumatologyRISKbusiness.industryIncidencenutritional and metabolic diseasesMiddle AgedOsteoarthritis Kneemedicine.diseaseDEPRESSIONRHEUMATOID-ARTHRITISKnee painRelative riskFemalemedicine.symptomHydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessmedicine.drugCohort study
researchProduct

Should low high-density lipoprotein cholesterol (HDL-C) be treated?

2014

The first observations linking a low serum level of HDL-C to increased risk for cardiovascular disease were made over 50 years ago. High serum levels of HDL-C appear to protect against the development of atherosclerotic disease, while low serum levels of this lipoprotein are among the most important predictors of atherosclerotic disease in both men and women and people of all racial and ethnic groups throughout the world. It has long been assumed that therapeutic interventions targeted at raising HDL-C levels would lower risk for such cardiovascular events as myocardial infarction, ischemic stroke, and death. Even after five decades of intensive investigation, evidence to support this assum…

Malemedicine.medical_specialtyStatinmedicine.drug_classEndocrinology Diabetes and MetabolismDiseaseLower riskNiacinlaw.inventionCoronary artery diseaseEndocrinologyRandomized controlled triallawRisk FactorsInternal medicinemedicineHumansMyocardial infarctionDyslipidemiasbusiness.industryReverse cholesterol transportCholesterol HDLFibric Acidsmedicine.diseaseEndocrinologyCardiovascular Diseaseslipids (amino acids peptides and proteins)FemaleThiazolidinedionesHydroxymethylglutaryl-CoA Reductase Inhibitorsbusinesscoronary artery disease fibrate high-density lipoproteins low-density lipoproteins niacin reverse cholesterol transport statin thiazolidinedioneNiacin
researchProduct

Effect of an educational program in primary care: the case of lipid control in cardio-cerebrovascular prevention.

2014

Lowering blood cholesterol levels reduces the risk of coronary heart disease. However, the effect of interventions depends on the patients' adherence to treatment. Primary care plays an important role in the detection, treatment and monitoring of disease, therefore different educational programs (EP) have been implemented to improve disease management in general practice. The present study is aimed to assess whether a general practitioner auditing and feedback EP may improve dyslipidaemia management in a primary care setting and to evaluate patients' adherence to prescribed lipid-lowering treatment. The quality of cardiovascular and cerebrovascular disease prevention before and after the i…

Malemedicine.medical_specialtyStatinmedicine.drug_classImmunologyPsychological interventionBlood lipidsAuditDiseaseMedication AdherenceGeneral PractitionersInternal medicineHealth caremedicineImmunology and AllergyHumansDisease management (health)AgedDyslipidemiasPharmacologyPrimary Health Carebusiness.industryMiddle AgedCerebrovascular DisordersCardiovascular DiseasesFemalebusinessEducational program
researchProduct

Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion.

2002

Abstract Background: Beneath its lipid-lowering properties additional non-lipid effects of statin therapy are discussed. We therefore examined the impact of statins on laboratory markers of coagulation, inflammation and soluble cell adhesion to further explore these effects in 950 hospitalised patients with angiographically proven CAD. Methods and results: Although no significant differences were found in total cholesterol, LDL and HDL and triglyceride levels a statistically lower value in 277 statin-treated patients was found for von Willebrand factor [162(130/224) vs. 208(154/283)%, P =0.0001], leukocyte count [6.9(5.8/8.4) vs. 7.3(6.1/9.4)/nl, P =0.0005], high sensitive CRP [4.3(1.8/10.8…

Malemedicine.medical_specialtyStatinmedicine.drug_classInflammationCoronary Artery DiseaseSystemic inflammationchemistry.chemical_compoundVon Willebrand factorInternal medicinevon Willebrand FactormedicineCell AdhesionHumansAgedbiologyTriglycerideCholesterolbusiness.industryAnticholesteremic AgentsCholesterol LDLMiddle AgedEndocrinologyCoagulationchemistryHMG-CoA reductasebiology.proteinFemalemedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBiomarkersInternational journal of cardiology
researchProduct

Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials

2013

The available data on statin effects in chronic kidney disease (CKD) patients are still conflicting. We investigated the impact of short- and long-term statin therapy on lipid profiles in CKD patients requiring or not requiring dialysis.Data from Scopus, PubMed, Web of Science, and the Cochrane Library from 1966 to May 2012 were searched for studies that investigated this effect. We included all randomized controlled clinical trials that investigated the impact of statin therapy on lipids and lipoproteins.The final analysis included 16 trials with 3594 subjects. In CKD patients, statin therapy significantly reduced total cholesterol (TC), triglycerides (TG) and low-density lipoprotein chole…

Malemedicine.medical_specialtyStatinmedicine.drug_classmedicine.medical_treatmentCochrane LibraryPharmacologylaw.inventionRandomized controlled trialRenal DialysislawInternal medicinemedicineHumansRenal Insufficiency ChronicCholesterol Chronic kidney disease Dialysis Hemodialysis Lipids Lipoproteins Meta-analysis StatinsDialysisRandomized Controlled Trials as Topicmedicine.diagnostic_testbusiness.industryGeneral Medicinemedicine.diseaseLipidsClinical trialFemalelipids (amino acids peptides and proteins)HemodialysisHydroxymethylglutaryl-CoA Reductase InhibitorsLipid profilebusinessKidney diseaseCurrent Medical Research and Opinion
researchProduct

Alpha 2-receptor-mediated inhibition of intraluminal release of gastric somatostatin in anaesthetized rats.

1992

Alino, S. F., Garcia, D. & Uvnas-Moberg, K. 1992. Alpha2-receptor-mediated inhibition of intraluminal release of gastric somatostatin in anaesthetized rats. Acta Physiol Scand144, 233–238. Received 22 February 1991, accepted 11 October 1991. ISSN 00014772. Department of Pharmacology and Pharmaceutics, University of Valencia, Valencia, Spain, Department of Cell Biology and Morphology Science, University of Pais Vasco, Leioa, Spain and Department of Pharmacology, Karolinska Institute, Stockholm, Sweden. The aim of the present study was to investigate how the sympathetic nervous system affects the vagally induced intragastric release of somatostatin and gastrin. Experiments were performed on a…

Malemedicine.medical_specialtySympathetic Nervous SystemPhysiologyNeuropeptideClonidinePhentolamineInternal medicineGastrinsmedicineAnimalsAnesthesiaPhentolamineGastrinbusiness.industryStomachdigestive oral and skin physiologyRats Inbred StrainsVagus NerveHydrogen-Ion ConcentrationReceptors Adrenergic alphaElectric StimulationVagus nerveRatsEndocrinologymedicine.anatomical_structureSomatostatinGastrointestinal hormoneGastric MucosabusinessSomatostatinPerfusionhormones hormone substitutes and hormone antagonistsmedicine.drugActa physiologica Scandinavica
researchProduct

Pravastatin treatment causes a shift in the balance of hippocampal neurotransmitter binding densities towards inhibition

2009

Since pravastatin, a HMG-CoA reductase inhibitor, has recently been shown to reduce infarct volumes and glutamate release in a rat model of ischemic stroke, the aim of the present study was to investigate whether this neuroprotective effect may be due to a modulation of excitatory and inhibitory neurotransmitter receptors. Therefore, Wistar rats were treated six times in 4 days with pravastatin or saline and allowed to survive for 6 hours or 5 days (n=10 per time point and group), respectively. Using quantitative receptor autoradiography, ligand binding densities of [(3)H]MK-801, [(3)H]AMPA, and [(3)H]muscimol for labeling of NMDA, AMPA, and GABA(A) receptors were analyzed in sensorimotor c…

Malemedicine.medical_specialtyTime FactorsKainate receptorAMPA receptorBiologyPharmacologyHippocampusReceptors N-Methyl-D-AspartateNeurotransmitter bindingRandom Allocationchemistry.chemical_compoundInternal medicinemedicineAnimalsReceptors AMPARats WistarLong-term depressionMolecular Biology5-HT receptorPravastatinCerebral CortexNeurotransmitter AgentsGABAA receptorGeneral NeuroscienceGlutamate receptorReceptors GABA-ACorpus StriatumRatsNeuroprotective AgentsEndocrinologynervous systemMuscimolchemistryNeurology (clinical)Developmental BiologyBrain Research
researchProduct